...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease.
【24h】

Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease.

机译:肥厚型心肌病的分子遗传学:对疾病的个体化管理。

获取原文
获取原文并翻译 | 示例

摘要

Hypertrophic cardiomyopathy is a relatively common genetic disease, affecting one person per 500 in the general population, and is clinically defined by the presence of unexplained left ventricular hypertrophy. Although recognized as the most common cause of sudden death in the young (especially in athletes), the cardiac expression of the disease is highly variable with respect to age at onset, degree of symptoms and risk of cardiac death. As a consequence, therapeutic strategies are diverse and must be adapted to the specific features of an individual. Recently, the molecular bases of the disease have been unraveled with the identification of a large number of mutations in genes encoding sarcomeric proteins. This review focuses on the impact of the molecular data on the understanding of the disease, and considers the emerging issues regarding the impact of molecular testing on the management of patients (or relatives) in clinical practice.
机译:肥厚型心肌病是一种相对常见的遗传性疾病,在普通人群中每500人中就有一个人受到感染,临床上由无法解释的左心室肥大的存在来定义。尽管公认是年轻人(尤其是运动员)猝死的最常见原因,但疾病的心脏表达在发病年龄,症状程度和心脏死亡风险方面存在很大差异。结果,治疗策略是多种多样的,必须适应个体的特定特征。最近,通过鉴定编码肌节蛋白的基因中的大量突变,已经阐明了该疾病的分子基础。这篇综述着重于分子数据对疾病理解的影响,并考虑了在临床实践中有关分子检测对患者(或亲属)管理的影响的新兴问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号